Amgen (AMGN)

• Market cap: $162B
• 1 day: -0.30%
• 5 days: -2.63%
• 1 month: 7.61%
• 3 months: 3.28%
• 6 months: 5.27%
• Year to date: 15.88%
• 1 year: -9.63%
• 5 years: 22.80%
• 10 years: 70.15%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 28,000

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 37 [Q4 2024] → 74 (+37) [Q1 2025]

91% more first-time investments, than exits

New positions opened: 247 | Existing positions closed: 129

18% more capital invested

Capital invested by funds: $112B [Q4 2024] → $131B (+$19.7B) [Q1 2025]

2% more funds holding

Funds holding: 2,813 [Q4 2024] → 2,875 (+62) [Q1 2025]

8% more call options, than puts

Call options by funds: $2.74B | Put options by funds: $2.55B

0.85% more ownership

Funds ownership: 77.62% [Q4 2024] → 78.47% (+0.85%) [Q1 2025]

4% less repeat investments, than reductions

Existing positions increased: 1,115 | Existing positions reduced: 1,165

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $261 13% downside
• Avg. target: $302 0% upside
• High target: $328 9% upside

8 analyst ratings

• positive: 2 25%
• neutral: 5 63%
• negative: 1 13%

B of A Securities Tim Anderson	13% downside $261	Underperform Maintained	23 Jul 2025
Citigroup Geoff Meacham	2% upside $305	Neutral Maintained	22 Jul 2025
UBS Trung Huynh	9% upside $326	Neutral Maintained	21 Jul 2025
Piper Sandler David Amsellem	9% upside $328	Overweight Reiterated	27 Jun 2025
Cantor Fitzgerald Carter Gould	2% upside $305	Neutral Reiterated	24 Jun 2025